SKELAXIN- metaxalone tablet

Šalis: Jungtinės Valstijos

kalba: anglų

Šaltinis: NLM (National Library of Medicine)

Veiklioji medžiaga:

Metaxalone (UNII: 1NMA9J598Y) (Metaxalone - UNII:1NMA9J598Y)

Prieinama:

Rebel Distributors Corp

INN (Tarptautinis Pavadinimas):

Metaxalone

Sudėtis:

Metaxalone 800 mg

Vartojimo būdas:

ORAL

Recepto tipas:

PRESCRIPTION DRUG

Terapinės indikacijos:

SKELAXIN (metaxalone) is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man. Known hypersensitivity to any components of this product. Known tendency to drug induced, hemolytic, or other anemias. Significantly impaired renal or hepatic function.

Produkto santrauka:

SKELAXIN (metaxalone) is available as an 800 mg oval, scored pink tablet inscribed with 8667 on the scored side and “S” on the other. Available in bottles of: 15 (NDC 21695-123-15) 30 (NDC 21695-123-30) 60 (NDC 21695-123-60) 90 (NDC 21695-123-90) Store at Controlled Room Temperature, between 15°C and 30°C (59°F and 86°F). Rx Only

Autorizacija statusas:

New Drug Application

Prekės savybės

SKELAXIN- METAXALONE TABLET
REBEL DISTRIBUTORS CORP
----------
SKELAXIN
(METAXALONE) TABLETS
DES CRIPTION
SKELAXIN (metaxalone) is available as an 800 mg oval, scored pink
tablet.
Chemically, metaxalone is 5-[(3,5- dimethylphenoxy)
methyl]-2-oxazolidinone. The empirical formula is
C
H NO , which corresponds to a molecular weight of 221.25. The
structural formula is:
Metaxalone is a white to almost white, odorless crystalline powder
freely soluble in chloroform,
soluble in methanol and in 96% ethanol, but practically insoluble in
ether or water.
Each tablet contains 800 mg metaxalone and the following inactive
ingredients: alginic acid, ammonium
calcium alginate, B-Rose Liquid, corn starch and magnesium stearate.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
The mechanism of action of metaxalone in humans has not been
established, but may be due to general
central nervous system depression. Metaxalone has no direct action on
the contractile mechanism of
striated muscle, the motor end plate or the nerve fiber.
PHARMACOKINETICS
The pharmacokinetics of metaxalone have been evaluated in healthy
adult volunteers after single dose
administration of SKELAXIN under fasted and fed conditions at doses
ranging from 400 mg to 800 mg.
Absorption
Peak plasma concentrations of metaxalone occur approximately 3 hours
after a 400 mg oral dose under
fasted conditions. Thereafter, metaxalone concentrations decline
log-linearly with a terminal half-life
of 9.0 ± 4.8 hours. Doubling the dose of SKELAXIN from 400 mg to 800
mg results in a roughly
proportional increase in metaxalone exposure as indicated by peak
plasma concentrations (C
) and
area under the curve (AUC). Dose proportionality at doses above 800 mg
has not been studied. The
absolute bioavailability of metaxalone is not known.
The single-dose pharmacokinetic parameters of metaxalone in two groups
of healthy volunteers are
shown in Table 1.
TABLE 1: MEAN (%CV) METAXALONE PHARMACOKINETIC PARAMETERS
DOSE (mg) C
(ng/mL) T
(h) AUC (ng•h/mL) T
(h)
CL/F (L/h)
400
983 (53)
3.3 (35)
7